NPPB and hypertrophic cardiomyopathy: No significant differences were observed in the distribution of BMI (p = 0.056), NYHA class (p = 0.089), coronary heart disease (p = 0.101), hypertrophic cardiomyopathy (p = 0.292), EF (p = 0.058), LA-ap (p = 0.572), NT-proBNP (p = 0.068), prolonged QTc (p = 0.388), ACEI or ARB or ARNI prescriptions (p = 0.464), B blocker medication (p = 0.895), and SGLT2i usage (p = 0.868) across the three groups.